- Helius Medical Technologies (TSX:HSM) CEO Philippe Deschamps will address the U.S. Congress tomorrow.
- At the invitation of the Brain Mapping Foundation, Mr Deschamps will update Congress on the latest developments in clinical neuroscience.
- In particular, Mr Deschamps will present thoughts on how neuromodulation can impact the outcome of Acquired Brain Injuries.
- Helius’s share price remains unchanged, with shares currently trading at $1.20 apiece.
Neurotech company Helius Medical Technologies (HSM) has announced that its CEO, Philippe Deschamps, will address the United States Congress tomorrow.
The Brain Mapping Foundation invited Mr Deschamps to brief Congress on the latest technologies, innovations, and policies in clinical neuroscience.
Mr Deschamps will also present thoughts on neuromodulation, and how it can impact the outcome of Acquired Brain Injuries.
His presentation on February 25th will be part of the Brain Mapping Foundation’s 9th annual congressional briefing.
“I am deeply honoured to participate in this congressional briefing, and thank the Brain Mapping Foundation for their invitation to participate. I am also deeply grateful for the commitment of Congress to discuss this very important topic,” said Mr Deschamps.
“With the high unmet medical need for innovative treatments for neurological conditions, it is encouraging that the private and public sector are joining forces to help these people in need.”
Helius’s share price remains unchanged, with shares currently trading at $1.20 apiece at 10:52am EST.
